miR-200 family expression is downregulated upon neoplastic progression of Barrett’s esophagus

Table 3 miRNA expression in Barrett’s esophagus and esophageal adenocarcinoma

miRNA	BE (n = 17)	Adeno carcinoma (n = 20)	BEC (n = 9)	P value (Kruskal-Wallis test)
miR-141	0.026 (0.023, 0.036)	0.012 (0.011, 0.025)	0.015 (0.01, 0.04)	0.033981
miR-200a	0.148 (0.126, 0.177)	0.057 (0.013, 0.042)	0.08 (0.017, 0.201)	0.000791
miR-200b	0.833 (0.75, 0.993)	0.387 (0.316, 0.572)	0.399 (0.258, 1.13)	0.000681
miR-200c	1.05 (0.929, 1.170)	0.551 (0.461, 0.939)	0.662 (0.438, 0.965)	0.0032312
miR-429	0.07 (0.062, 0.087)	0.039 (0.029, 0.06)	0.042 (0.036, 0.09)	0.013551

Relative expression for each tissue type. Relative expression values are median (95% CI). BE = Barrett’s esophagus epithelium from individuals without cancer, BEC = Barrett’s epithelium taken proximal to adenocarcinoma and confirmed by histology to be free of invasive cancer. The group P value was the result of a Kruskal-Wallis test across the three tissue groups. Significant differences were identified by post hoc testing by Holm-Bonferroni method for:

¹Adenocarcinoma versus Barrett’s esophagus mucosa from individuals without cancer - miR-141 (P = 0.0126), miR-200a (P = 0.0001), miR-200b (P < 0.0001), and miR-200c (P = 0.0014) and miR-429 (P = 0.0031);

²Barrett’s esophagus mucosa from individuals with versus without cancer - miR-200c (P = 0.0191).